“Isofol will help extend life and improve the quality of life for cancer patients by offering the drug arfolitixorin”
Isofol is focused on making arfolitixorin available worldwide and thereby improving the quality of life for patients with cancer being treated with 5-FU-based therapies.
- Ensure the completion of the AGENT study for CRC
- Ensure that we can apply for regulatory approval for arfolitixorin as soon as possible after the end of the study
- Implement the company’s commercialization plan to enable the successful launch of arfolitixorin
- Assess strategic partnerships to maximize the potential and value of arfolitixorin
- Investigate extended uses of arfolitixorin through life cycle activities
Develop arfolitixorin in oncology
Isofol is a biotech company with the goal of bringing arfolitixorin to market. The drug is intended to reduce the tumor burden, improve the quality of life and extend the lives of CRC patients. The ongoing AGENT study is focused on the treatment of metastatic CRC (mCRC), where the medical need is high. With the current treatment options, only 10 percent of mCRC patients are alive five years after diagnosis. The company will also evaluate whether arfolitixorin can be effective for other forms of cancer and thus help more patients.
Isofol has built an organization with key expertise on staff, supplemented through partnerships that ensure the best possible access to the resources not provided by the organization’s own employees.
Commercial strategy and business model
To ensure that arfolitixorin can be launched immediately after receiving regulatory approval, Isofol will develop a full commercialization strategy. This strategy is to be completed before submitting an application for market approval to regulatory authorities. This approach is designed to prepare the company to commercialize arfolitixorin on its own as well as to strengthen its negotiating position with future partners. Isofol continuously evaluates various strategic partnerships, and if an agreement with a partner increases the value of arfolitixorin, we will consider it.
Last updated 07-06-2022